Login Register Cart 0
Generic placeholder image

当代肿瘤药物靶点

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Research Article

CYP1A1和CYP2D6基因多态性与慢性粒细胞白血病的易感性

卷 20, 期 9, 2020

页: [675 - 680] 页: 6

弟呕挨: 10.2174/1570163817666200518081356

价格: $65

conference banner
摘要

背景：CYP1A1和CYP2D6都是属于CYP450酶家族的异种生物代谢酶。这些基因的多态性因人而异，导致对致癌物质和药物的敏感性不同。 目的：前瞻性研究CYP1A1 * 2C和CYP2D6 * 4基因多态性对慢性粒细胞白血病（CML）易感性的影响。 方法：采用PCR-RFLP技术，从300名参与者（200名患者和100名健康个体）的血液样本中检测出CYP1A1 * 2C和CYP2D6 * 4的患病率。 结果：在我们的研究人群中，CYP1A1 Ile / Val和Val / Val基因型频率在CML患者中分别为82％和15％，在对照组中分别为55％和8％。这表明携带者具有较高的风险（OR = 18.38，95％CI = 7.364-45.913，p值; = 0.000和OR = 23.125,95％CI = 7.228-73.980，p值= 0.000）。携带CYP2D6杂合基因型（IM）的个体在CML组中的数量明显减少，为43.5％，而对照组为93％。这表明IM基因型可能在降低CML风险中具有预防功能（OR = 0.036，95％CI = 0.005-0.271，p值= 0.001）。尽管CML患者的纯合突变（PM）基因型分布较高（87％，而对照组为6％），但该差异被认为是无意义的（OR = 0.558，95％CI = 0.064- 4.845，p值＝ 0.597）。 结论：这些发现表明CYP1A1和CYP2D6多态性基因影响CML的易感性。

关键词: 白血病，CML，CYP1A1，CYP2D6，多态性，苏丹

« Previous Next »
[1]
Sailaja, K.; Vishnupriya, S.; Surekha, D.; Rao, D.N.; Rao, D. Association of CYP2D6* 4 polymorphism with chronic myeloid leukemia. JMSR, 2007, 1(1), 43-46.
[2]
Kassogue, Y.; Dehbi, H.; Quachouh, M.; Quessar, A.; Benchekroun, S.; Nadifi, S. Association of glutathione S-transferase (GSTM1 and GSTT1) genes with chronic myeloid leukemia. Springerplus, 2015, 4(1), 210.
[http://dx.doi.org/10.1186/s40064-015-0966-y] [PMID: 25969820]
[3]
Dhaval, K. Patel, D. J. S. Xenobiotics: An essential precursor for living system. Am J Adv Drug Deliv, 2016, 1(3), 262-270.
[4]
Lakkireddy, S.; Aula, S.; Avn, S.; Kapley, A.; Rao Digumarti, R.; Jamil, K. Association of the common CYP1A1*2C variant (Ile462Val Polymorphism) with chronic myeloid leukemia (CML) in patients undergoing imatinib therapy. Cell J., 2015, 17(3), 510-519.
[PMID: 26464823]
[5]
Lu, J.; Zhao, Q.; Zhai, Y.J.; He, H.R.; Yang, L.H.; Gao, F.; Zhou, R.S.; Zheng, J.; Ma, X.C. Genetic polymorphisms of CYP1A1 and risk of leukemia: A meta-analysis. OncoTargets Ther., 2015, 8, 2883-2902.
[http://dx.doi.org/10.2147/OTT.S92259] [PMID: 26491362]
[6]
Mukry, S.N.; Shahni, A.; Zaidi, U.; Shamsi, T.S. Cytochromes P450 and glutathione S-transferases polymorphisms: Can they predict efficacy of tyrosine kinase inhibitors in chronic myeloid leukemia? Blood, 2019, 134(Suppl. 1), 5920.
[7]
Chen, H.C.; Hu, W.X.; Liu, Q.X.; Li, W.K.; Chen, F.Z.; Rao, Z.Z.; Liu, X.F.; Luo, Y.P.; Cao, Y.F. Genetic polymorphisms of metabolic enzymes CYP1A1, CYP2D6, GSTM1 and GSTT1 and leukemia susceptibility. Eur. J. Cancer Prev., 2008, 17(3), 251-258.
[http://dx.doi.org/10.1097/CEJ.0b013e3282b72093] [PMID: 18414197]
[8]
Stejskalova, L.; Pavek, P. The function of cytochrome P450 1A1 enzyme (CYP1A1) and aryl hydrocarbon receptor (AhR) in the placenta. Curr. Pharm. Biotechnol., 2011, 12(5), 715-730.
[http://dx.doi.org/10.2174/138920111795470994] [PMID: 21342125]
[9]
Ezzeldin, N.; El-Lebedy, D.; Darwish, A.; El-Bastawisy, A.; Hassan, M.; Abd El-Aziz, S.; Abdel-Hamid, M.; Saad-Hussein, A. Genetic polymorphisms of human cytochrome P450 CYP1A1 in an Egyptian population and tobacco-induced lung cancer. Genes Environ., 2017, 39(1), 7-15.
[http://dx.doi.org/10.1186/s41021-016-0066-4] [PMID: 28074113]
[10]
Abbas, A.; Delvinquiere, K.; Lechevrel, M.; Lebailly, P.; Gauduchon, P.; Launoy, G.; Sichel, F. GSTM1, GSTT1, GSTP1 and CYP1A1 genetic polymorphisms and susceptibility to esophageal cancer in a French population: Different pattern of squamous cell carcinoma and adenocarcinoma. World J. Gastroenterol., 2004, 10(23), 3389-3393.
[http://dx.doi.org/10.3748/wjg.v10.i23.3389] [PMID: 15526353]
[11]
Al-Achkar, W.; Azeiz, G.; Moassass, F.; Wafa, A. Influence of CYP1A1, GST polymorphisms and susceptibility risk of chronic myeloid leukemia in Syrian population. Med. Oncol., 2014, 31(5), 889.
[http://dx.doi.org/10.1007/s12032-014-0889-4] [PMID: 24671854]
[12]
Surekha, D.; Sailaja, K.; Rao, D.N.; Padma, T.; Raghunadharao, D.; Vishnupriya, S. Association of CYP1A1*2 polymorphisms with breast cancer risk: A case control study. Indian J. Med. Sci., 2009, 63(1), 13-20.
[http://dx.doi.org/10.4103/0019-5359.49077] [PMID: 19346634]
[13]
Joseph, T.; Kusumakumary, P.; Chacko, P.; Abraham, A.; Radhakrishna Pillai, M. Genetic polymorphism of CYP1A1, CYP2D6, GSTM1 and GSTT1 and susceptibility to acute lymphoblastic leukaemia in Indian children. Pediatr. Blood Cancer, 2004, 43(5), 560-567.
[http://dx.doi.org/10.1002/pbc.20074] [PMID: 15382273]
[14]
Zanger, U.M.; Schwab, M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther., 2013, 138(1), 103-141.
[http://dx.doi.org/10.1016/j.pharmthera.2012.12.007] [PMID: 23333322]
[15]
Wilkinson, G.R. Drug metabolism and variability among patients in drug response. N. Engl. J. Med., 2005, 352(21), 2211-2221.
[http://dx.doi.org/10.1056/NEJMra032424] [PMID: 15917386]
[16]
Wang, X.; Li, J.; Dong, G.; Yue, J. The endogenous substrates of brain CYP2D. Eur. J. Pharmacol., 2014, 724, 211-218.
[http://dx.doi.org/10.1016/j.ejphar.2013.12.025] [PMID: 24374199]
[17]
Surekha, D.; Sailaja, K.; Rao, D.N.; Padma, T.; Raghunadharao, D.; and Vishnupriya, S. CYP2D6*4 polymorphisms and breast cancer risk. Biol. Med. (Aligarh), 2010, 4(2), 49-55.
[18]
Zhou, S.F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin. Pharmacokinet., 2009, 48(12), 761-804.
[http://dx.doi.org/10.2165/11318070-000000000-00000] [PMID: 19902987]
[19]
Gomes, L.; Lemos, M.C.; Paiva, I.; Ribeiro, C.; Carvalheiro, M.; Regateiro, F.J. CYP2D6 genetic polymorphisms are associated with susceptibility to pituitary tumors. Acta Med. Port., 2005, 18(5), 339-343.
[PMID: 16611538]
[20]
Anwarullah; Aslam, M.; Badshah, M.; Abbasi, R.; Sultan, A.; Khan, K.; Ahmad, N.; von Engelhardt, J. Further evidence for the association of CYP2D6*4 gene polymorphism with Parkinson’s disease: A case control study. Genes Environ., 2017, 39(1), 18-24.
[http://dx.doi.org/10.1186/s41021-017-0078-8]
[21]
Lee, J.Y.; Vinayagamoorthy, N.; Han, K.; Kwok, S.K.; Ju, J.H.; Park, K.S.; Jung, S.H.; Park, S.W.; Chung, Y.J.; Park, S.H. Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus. Arthritis Rheumatol., 2016, 68(1), 184-190.
[http://dx.doi.org/10.1002/art.39402] [PMID: 26316040]
[22]
Taspinar, M.; Aydos, S.E.; Comez, O.; Elhan, A.H.; Karabulut, H.G.; Sunguroglu, A. CYP1A1, GST gene polymorphisms and risk of chronic myeloid leukemia. Swiss Med. Wkly., 2008, 138(1-2), 12-17.
[PMID: 18224491]
[23]
Shahab, L.; Goniewicz, M.L.; Blount, B.C.; Brown, J.; McNeill, A.; Alwis, K.U.; Feng, J.; Wang, L.; West, R. Nicotine, carcinogen, and toxin exposure in long-term e-cigarette and nicotine replacement therapy users: A cross-sectional study. Ann. Intern. Med., 2017, 166(6), 390-400.
[http://dx.doi.org/10.7326/M16-1107] [PMID: 28166548]
[24]
Nagai, F.; Hiyoshi, Y.; Sugimachi, K.; Tamura, H.O. Cytochrome P450 (CYP) expression in human myeloblastic and lymphoid cell lines. Biol. Pharm. Bull., 2002, 25(3), 383-385.
[http://dx.doi.org/10.1248/bpb.25.383] [PMID: 11913539]
[25]
Farnaz Razmkhah, Vahid Pazhakh; Farhad, Zaker.; Farzaneh, Atashrazm.; Maryam, Sheikhi. Frequency of CYP1A1*2C polymorphism in patients with leukemia in the iranian population. Lab. Med., 2011, 42(4), 220-223.
[http://dx.doi.org/10.1309/LM337JWOSVNEHPUI]
[26]
Sabitha, K.; Reddy, M.V.; Jamil, K. Smoking related risk involved in individuals carrying genetic variants of CYP1A1 gene in head and neck cancer. Cancer Epidemiol., 2010, 34(5), 587-592.
[http://dx.doi.org/10.1016/j.canep.2010.05.002] [PMID: 20887941]
[27]
Ovsepian, V.A.; Vinogradova, E.Iu.; Sherstneva, E.S. Cytochrome P4501A1, glutathione S-transferase M1 and T1 gene polymorphisms in chronic myeloid leukemia. Genetika, 2010, 46(10), 1360-1362.
[PMID: 21254556]
[28]
Khedhaier, A.; Hassen, E.; Bouaouina, N.; Gabbouj, S.; Ahmed, S.B.; Chouchane, L. Implication of xenobiotic metabolizing enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) polymorphisms in breast carcinoma. BMC Cancer, 2008, 8, 109.
[http://dx.doi.org/10.1186/1471-2407-8-109] [PMID: 18423013]
[29]
Lemos, M.C.; Carrilho, F.; Rodrigues, F.; Coutinho, E.; Gomes, L.; Carvalheiro, M.; Regateiro, F.J. Genetic polymorphism of CYP2D6 influences susceptibility to papillary thyroid cancer. Clin. Endocrinol. (Oxf.), 2007, 67(2), 180-183.
[http://dx.doi.org/10.1111/j.1365-2265.2007.02858.x] [PMID: 17547692]
[30]
Wolf, C.R.; Smith, C.A.; Gough, A.C.; Moss, J.E.; Vallis, K.A.; Howard, G.; Carey, F.J.; Mills, K.; McNee, W.; Carmichael, J. Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis, 1992, 13(6), 1035-1038.
[http://dx.doi.org/10.1093/carcin/13.6.1035] [PMID: 1600608]
[31]
Lemos, M.C.; Cabrita, F.J.; Silva, H.A.; Vivan, M.; Plácido, F.; Regateiro, F.J. Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias. Carcinogenesis, 1999, 20(7), 1225-1229.
[http://dx.doi.org/10.1093/carcin/20.7.1225] [PMID: 10383893]
[32]
Roddam, P.L.; Rollinson, S.; Kane, E.; Roman, E.; Moorman, A.; Cartwright, R.; Morgan, G.J. Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia. Pharmacogenetics, 2000, 10(7), 605-615.
[http://dx.doi.org/10.1097/00008571-200010000-00004] [PMID: 11037802]

Rights & Permissions Print Cite
Article Metrics
18
3
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy